Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Public ClinicalTrials.gov record NCT00661427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m^2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer.
Study identification
- NCT ID
- NCT00661427
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- cetuximab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2007
- Primary completion
- Jul 31, 2012
- Completion
- Jul 31, 2012
- Last update posted
- Jan 10, 2018
2007 – 2012
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010-3000 | — |
| H. Lee Moffit Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| NorthShore University Health System | Evanston | Illinois | 60201 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-7680 | — |
| Memorial Sloan-Kettering Cancer Center at Basking Ridge | Basking Ridge | New Jersey | 07939 | — |
| Memorial Sloan-Kettering Cancer Center at Commack | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan-Kettering at Mercy Medical Center | Rockville Centre | New York | — | — |
| Memoral Sloan Kettering Cancer Center@Phelps | Sleepy Hollow | New York | — | — |
| Fox Chase Virtua Health Cancer Program | Philadelphia | Pennsylvania | 08060 | — |
| University of Pennsylvania - Abramson Cancer Center | Philadelphia | Pennsylvania | 19104-4283 | — |
| Abramson Cancer Center University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Pennsylvania Hospital | Philadelphia | Pennsylvania | 19106 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Tennessee Cancer Institute | Memphis | Tennessee | 38104 | — |
| Huntsman Cancer Institue | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00661427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2018 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00661427 live on ClinicalTrials.gov.